How to use the speech recognition tool?

NCT03507686

Gemini

An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral,
Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1).

Type: Interventional



Status of the trial: Active, Not recruiting

Orphan Drug Recognition: Yes

Inclusion

  • Opening Date: 2018-02-01
  • Closing Date: 2019-02-01

Criteria

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe

* indicates required

This ERN is supported by: